Preoperative serum C-reactive protein and gastric cancer; Clinical-pathological correlation and prognostic significance

Chang Gung Medical Journal

Volumn 33, Issue 3, 2010, Pages 301-312

  Chang, Cheng Chih ^a   Sun, Chien Feng ^b   Pai, Hung Jia ^a   Wang, Wen Ke ^a   Hsieh, Ching Chuan ^a   Kuo, Liang Mou ^a   Wang, Chia Siu ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

C reactive protein; Gastric cancer; Inflammatory biomarker; Prognostic factor

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; AGE; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INFILTRATION; CANCER PATIENT; CANCER SIZE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SEROSA; STOMACH CANCER; SURVIVAL RATE; BLOOD; MIDDLE AGED; MORTALITY; PATHOLOGY; STOMACH TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS;

EID: 77954531058     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Department of Health, Executive Yuan, Taiwan, ROC. Analysis of main causes of death. In: 2007 statistics of death cause in Taiwan. 2008:22-3.
2. Jemal A, Siegel R, Ward E, Hao YP, Xu J, Murray T, Thun MJ; American Cancer Society. Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96.
3. Lee JK, Inoue M, Otani T, Iwasaki M, Sasazuki S, Tsugane S. Gastric cancer screening and subsequent risk of gastric cancer: A large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 2006;118:2315-21.
4. Wang CS, Hsieh CC, Chao TC, Jan YY, Jeng LB, Hwang TL, Chen MF, Chen PC, Chen JS, Hsueh S. Resectable gastric cancer: operative mortality and survival analysis. Chang Gung Med J 2002;25:216-27.
5. Marrelli D, Roviello F, De Stefano A, Farnetani M, Garosi L, Messano A, Pinto E. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology 1999;57:55-62.
6. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005;8:86-94.
7. Tillet WS, Francis T. Serological reaction in pneumonia with a non-protein somatic fraction of pnemoncoccus. J Exp Med 1930;52:561-71.
8. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes; regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990;12:1179-86.
9. Zimmerman MA, Selzman CH, Cothren C, Sorensen AC, Raeburn CD, Harken AH. Diagnostic implications of C-reactive protein. Arch Surg 2003;138:220-4.
10. Ledue TB, Weiner DL, Sipe J, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A, and mannose binding protein in human serum. Ann Clin Biochem 1998;35:745-53.
11. Kushner I, Rzewnicki D, Damols D. What does minor elevation of C-reactive protein signify? Am J Med 2006;119:166.e17-28.
12. Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007;61:824-33.
13. Gockel I, Dirksen K, Messow CM, Junginger T. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol 2006;12:3746-50.
14. Crumley ABC, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastrooesophageal cancer. Br J Cancer 2006;94:1568-71.
15. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003;90:215-9.
16. Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R, Imrie CW. Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma of pancreas. Br J Cancer 2005;92:21-3.
17. Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, Adachi H, Kurogi J, Tajiri N, Inoue K, Niizeki T, Koga H, Imaizumi T, Kojiro M, Sata M. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int 2007;27:1091-7.
18. Lamb GWA, McMillan DC, Ramsey S, Aitchison M. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer 2006;94:781-4.
19. Ward AM, Cooper EH, Houghton AI. Acute phase reactant protein in prostate cancer. Br J Urol 1977;49:411-8.
20. Hilmy M, Campbell R, Bartlett JMS, McNicol AM, Underwood MA, McMillan DC. The relationship between the systemic inflammatory response, tumor proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 2006;95:1234-8.
21. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, Tempfer CB, Reinthaller A. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008;14:710-4.
22. Polterauer S, Grimm C, Tempfer C, Sliutz G, Speiser P, Reinthaller A, Hefler LA. C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol 2007;107:114-7.
23. De Mello J, Struthers L, Turner R, Cooper EH, Giles GR. Multivariate analyses as aids to diagnosis and assessment of prognosis in gastrointestinal cancer. Br J Cancer 1983;48:341-8.
24. Wu CW, Lui WY, P'eng FK, Wang SR. Alterations of humoral immunity in patients with gastric cancer. Asian Pac J Allergy Immunol 1988;6:7-10.
25. Ilhan N, Ilhan N, Ilhan Y, Akbulut H, Kucuksu M. C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol 2004;10:1115-20.
26. Tsavaris N, Kosmas C, Kopterides P, Tsikalakis D, Skopelitis H, Sakelaridi F, Papadoniou N, Tzivras M, Balatsos V, Koufos C, Archimandritis A. Retinol-binding protein, acute phase reactants and Helicobacter pylori infection in patients with gastric adenocarcinoma. World J Gastroenterol 2005;11:7174-8.
27. Yamashita H, Kitayama J, Nagawa H. Hyperfibrinogenemia is a useful predictor for lymphatic metastasis in human gastric cancer. Jpn J Clin Oncol 2005;35:595-600.
28. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma -2nd English edition. Gastric Cancer 1998;1:10-24.
29. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002:99-106.
30. Wu JT. Clinical application. In: Wu JT, Nakamura RM, eds. Human Circulating Tumor markers: Current Concepts and Clinical Applications. Chicago: American Society of Clinical Pathologists, 1997:21-36.
31. Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003;4:224-32.
32. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003;90:215-9.
33. McArdle PA, McMillan DC, Sattar N, Wallace AM, Underwood MA. The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease. Br J Cancer 2004;91:1755-7.
34. Hayashi H, Ochiai T, Shimada H, Gunji Y. Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. Surg Endosc 2005;19:1172-6.
35. Adachi Y, Shiraishi N, Shiromizu A, Bandoh T, Aramaki M, Kitano S. Laparoscopy-assisted Billroth I gastrectomy compared with conventional open gastrectomy. Arch Surg 2000;135:806-10.
36. Mustard RA Jr., Bohnen JM, Haseeb S, Kasina R. C-reactive protein levels predict postoperative septic complications. Arch Surg 1987;122:69-73.
37. Sakaguchi S, Takifuji K, Arita S, Yamaue H. Development of an early diagnostic system using fuzzy theory for postoperative infections in patients with gastric cancer. Dig Surg 2004;21:210-4.
38. Perwez Hussain S, Harris CC. Inflammation and cancer: an ancient link with novel potentials. In J Cancer 2007;121:2373-80.
39. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
40. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001:49:347-53.
41. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-40.
42. Caruso R, Pallone F, Monteleone G. Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. World J Gastroenterol 2007;13:5547-51.
43. Yamaoka Y, Kita M, Kodama T, Sawai N, Imanishi J. Helicobacter pylori Cag A gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 1996;110:1744-52.
44. Saribas S, Kocazeybek B, Aslan M, Altun S, Seyhun Y, Oner YA, Memisoglu N. Do procalcitonin and C-reactive protein levels have a place in the diagnosis and follow-up of Helicobacter pylori infections? J Med Microbiol 2004;53(Pt 7):639-44.
45. Hung YB, Wang CS, Hsueh S, Hwang TL, Chen MF. Helicobarter pylori in surgical specimens from patients with resectable gastric adenocarcinoma. Chang Gung Med J 1998;21:179-83.
46. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS; China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94.
47. Porter JD, Ulrich CM. COX-2 and gastric cancer: more on inflammation and neoplasia. Gastroenterology 2005;130:2198-200.
48. Chang YJ, Wu MS, Lin JT, Chen CC. Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. J Immunol 2005;175:8242-52.
49. Tsuji S, Tsujii M, Murata H, Nishida T, Komori M, Yasumaru Mu, Ishii S, Sasayama Y, Kawano S, Hayashi N. Helicobacter pylori eradication to prevent gastric cancer: underlying molecular and cellular mechanisms. World J Gastroenterol 2006;12:1671-80.
50. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006;24:33-50.
51. Lee DS, Moss SF. COX-2 inhibition and the prevention of gastric cancer. Digestion 2006;74:184-6.
52. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and metaanalysis. J Natl Cancer Inst 2003;95:1784-91.